Pioglitazone monotherapy improves daily plasma glucose and insulin concentrations in type 2 diabetic subjects: A double-blind, placebo-controlled trial

Journal of Medical Sciences

Volumn 26, Issue 1, 2006, Pages 19-24

  Hung, Yi Jen ^a   Pei, Dee ^b   Kuo, Shi Wen ^b   Hsieh, Chien Hsing ^a   He, Chih Tsueng ^a   Shen, Der Chung ^c   Sheu, Wayne Huey Herng ^d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c Chung Shan Hospital   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Insulin sensitivity; Pioglitazone; Postprandial metabolism

Indexed keywords

GLUCOSE; INSULIN; LIPID; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUANTITATIVE ANALYSIS;

EID: 33644891034     PISSN: 10114564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;(32Suppl 3):35-45.
2. Boden G. Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am 2001;30: 801-815.
3. Pratley RE, Weyer C. Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion. Curr Diab Rep 2002;2:242-248.
4. Mitrakou A. Pathogenesis of hyperglycaemia in type 2 diabetes. Diabetes Obes Metab 2002;4:249-254.
5. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Postprandial state and atherosclerosis. Curr Opin Lipidol 1995;6:286-290.
6. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000;16:125-132.
7. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-B29.
8. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20:1822-1826.
9. Donahue RP, Abbott RD, Reed DM, Yano K. Post-challenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36:689-692.
10. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-1405.
11. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17:211-217.
12. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17.
13. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. A summary analysis. Arterioscler Thromb Vasc Biol 2003;23:1744-1749.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-1611.
16. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-719.
17. Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002;34:589-595.
18. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997;350(Suppl 1):SI20-SI23.
19. Shimono D, Kuwamura N, Nakamura Y, Koshiyama H. Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes. Diabetes Care 2001;24:971.
20. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449-452.